Evidence map›Paper›PMID 28761118›Full record

Trial reportLeukemia2018

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

H Goldschmidt, H M Lokhorst, E K Mai, B van der Holt, I W Blau, S Zweegman, K C Weisel, E Vellenga, M Pfreundschuh, M J Kersten and 22 more

Open access · bronzeAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 7 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 7 syntheses or guidelines pooled it, 198 citations in OpenAlex.

  1. Pooled it
  2. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Guideline
  3. Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Review
  20. Choosing the optimal maintenance strategy in multiple myeloma.Hematology. American Society of Hematology. Education Program · 2025
    Review

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 3 countries.

H GoldschmidtDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
H M LokhorstDepartment of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
E K MaiDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
B van der HoltHOVON Data Center, Department of Hematology, Erasmus MC Cancer Center, Rotterdam, The Netherlands.
I W BlauInternal Medicine, Charité University Medicine Berlin, Berlin, Germany.
S ZweegmanDepartment of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
K C WeiselDepartment of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany.
E VellengaDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
M PfreundschuhDepartment of Hematology and Oncology, University Clinic of Saarland, Homburg, Germany.
M J KerstenHematology, Academic Medical Center, Amsterdam, The Netherlands.
C ScheidDepartment I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
S CroockewitDeptartment of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
R RaymakersDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
D HoseDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
A PotamianouEMEA Medical, Janssen, Athens, Greece.
A JauchInstitute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
J HillengassDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
M Stevens-KroefLaboratorium Tumor Genetica, Radboud University Medical Centre, Nijmegen,The Netherlands.
M S RaabDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
A BroijlDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
H W LindemannKlinik für Hämatologie/Onkologie, Kath. Krankenhaus Hagen gem. GmbH - St-Marien-Hospital, Hagen, Germany.
G M J BosDeptartment of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands.
P BrossartInternal Medicine III, Oncology, Hematology and Rheumatology, University Clinic Bonn, Bonn, Germany.
M van Marwijk KooyDepartment of Hematology, Isala Clinics, Zwolle, The Netherlands.
P YpmaDepartment of Hematology, Haga Hospital, The Hague, The Netherlands.
U DuehrsenDepartment of Hematology, University Hospital Essen, Essen, Germany.
R M SchaafsmaDepartment of Hematology, Medisch Spectrum Twente, Enschede, The Netherlands.
U BertschDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
T HielscherDivision of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.ORCID 0000-0003-1277-310X
Le JarariHOVON Datacenter, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
H J SalwenderDepartment of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany.
P SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Heidelberg University · DEErasmus MC Cancer Institute · NLRadboud University Nijmegen · NLAmsterdam UMC Location University of Amsterdam · NLAmsterdam UMC Location Vrije Universiteit Amsterdam · NLAsklepios Klinik Altona · DEAthens Medical Center · GRCancer Center Amsterdam · NLCharité - Universitätsmedizin Berlin · DEEssen University Hospital · DEGerman Cancer Research Center · DEHaga Hospital · NLIsala · NLMaastricht University Medical Centre · NLMedisch Spectrum Twente · NLSaarland University · DESt. Marien Hospital · DEUniversity Hospital Bonn · DEUniversity Medical Center Groningen · NLUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR)=0.76, 95% confidence interval (95% CI) of 0.65-0.89, P=0.001). Overall survival (OS) was similar in the PAD versus VAD arm (HR=0.89, 95% CI: 0.74-1.08, P=0.24). The incidence of SPM were similar between the two arms (7% each, P=0.73). The negative prognostic effects of the cytogenetic aberration deletion 17p13 (clone size ⩾10%) and renal impairment at baseline (serum creatinine >2 mg dl

Indexed as

AdolescentAdultAgedBortezomibChromosome AberrationsFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansMaleMelphalanMiddle AgedMultiple MyelomaPrognosisProgression-Free SurvivalThalidomideBortezomibMelphalanThalidomide

Identifiers

PMID28761118
OpenAlexW2727891259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.